An interventional study of Femtosecond laser-assisted cataract surgery using Zero CDE in Cataract With a Nuclear Sclerosis Grade Between 1 to 3, sponsored by Bochner Eye Institute. Not yet recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Bochner Eye Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Cataract with a site in Canada — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Canada.
Among the 33 studies in Cataract with a site in Canada, this one is the 9th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, and was the 32nd registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →3 of the 33 studies in Cataract with a site in Canada are open now. Recruiting first, the newest first:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 65+ · Healthy volunteers
Uptown Eye Specialists · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 90 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 68 across the 23 interventional studies, 123 across the 10 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bochner Eye Institute as lead sponsor.
Bochner Eye Institute has 1 study filed under Cataract — fewer than ten, so there is no comparison to draw.
2 of the studies in Cataract with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404293Bochner Eye InstituteZero CDE Technique for Lens Removal During FLACS | 2027-03-14 |
| NCT07714174Samuel Lunenfeld Research Institute, Mount Sinai HospitalPost-operative Cognitive Decline After Ambulatory Cataract Surgery in the Elderly Population | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Cataract with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Zero CDE (cumulative dissipated energy) technique facilitates cataract removal with no or minimal phaco energy. This is facilitated by a femtosecond laser, which pre-divides the cataractous lens nucleus into multiple small segments that can be aspirated without phaco energy being delivered to the eye. In the investigator's experience, this technique consistently shows a stable anterior chamber, a low complication rate, and a rapid return of vision following cataract surgery. This prospective study aims to document the outcomes with the zero CDE technique during femtosecond laser-assisted cataract surgery (FLACS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a single-arm, non-comparative, prospective study including cataract patients with a nuclear sclerosis grade between 1 to 3 who desire to undergo cataract surgery and IOL implantation at Bochner Eye Institute, Canada.
Procedure: Femtosecond laser-assisted cataract surgery using Zero CDE
In this single-arm, non-comparative study, patients with cataract grade 1-3 (LOCS III nuclear sclerosis) will undergo cataract removal with the Zero CDE technique that involves no or minimal phaco energy. This is facilitated by a femtosecond laser, which pre-divides the cataractous lens nucleus into multiple small segments that can be aspirated without phaco energy being delivered to the eye.
% of cataract cases completed with Zero CDE
Time frame: Intraoperative
Among the cataract cases with zero CDE, o the average amount of balanced salt solution (BSS) (ml) used per case.
Time frame: Intraoperative
Among the cataract cases with zero CDE o % of cataract cases with corneal edema at one-day postop.
Time frame: Postoperative Day 1
Among the cataract cases with zero CDE o % of cataract cases with CME at any time up to 3 months postop.
Time frame: Postoperative 2 weeks, 1 month and 3 months
Among the cases requiring CDE, the amount of phaco energy used
Time frame: Intraoperative
Incidence of adverse events
Time frame: Intraoperative, and postoperative Day 1, 2 weeks, 1 month, and 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Mar 2027, 11 months later.
Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 11 months is below that.
Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.